Stifel Nicolaus Remains a Hold on Biogen Inc

By Carrie Williams

In a report issued on October 8, Thomas Shrader from Stifel Nicolaus reiterated a Hold rating on Biogen Inc (NASDAQ: BIIB), with a price target of $300. The company’s shares closed yesterday at $333.19, close to its 52-week high of $333.33.

According to TipRanks.com, Shrader is a top 100 analyst with an average return of 39.3% and a 61.5% success rate. Shrader covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Voyager Therapeutics Inc, and Molecular Templates Inc.

Currently, the analyst consensus on Biogen Inc is Moderate Buy and the average price target is $325.07, representing a -2.4% downside.

In a report issued on September 28, Robert W. Baird also reiterated a Hold rating on the stock with a $290 price target.

Biogen Inc’s market cap is currently $70.45B and has a P/E ratio of 21.88. The company has a book value ratio of 6.0808.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A.